Claims for Patent: 8,912,148

Summary for Patent: 8,912,148

Title:	Methods of treating a disease or condition associated with abnormal angiogenesis
Abstract:	The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.
Inventor(s):	Bradshaw; Curt (San Diego, CA), Bhat; Abhijit (Encinitas, CA), Lai; Jing Yu (San Diego, CA), Doppalapudi; Venkata (San Diego, CA), Liu; Dingguo (San Diego, CA)
Assignee:	Covx Technology Ireland, Ltd. (Dublin, IE)
Application Number:	13/584,721
Patent Claims:	1. A method for treating a disease or symptom associated with an angiogenic disorder, comprising administering to the subject a therapeutically effective amount of an AA targeting compound, salt, of the formula: TABLE-US-00037 (SEQ ID NO: 43) R.sup.1-Q.sup.1 (A.sub.cK).sup.2 Y.sup.3 Q.sup.4 P.sup.5 L.sup.6 D.sup.7 E.sup.8 (A.sub.cK).sup.9 D.sup.10 K.sup.11 T.sup.12 L.sup.13 Y.sup.14 D.sup.15 Q.sup.16 F.sup.17 M.sup.18 L.sup.19 Q.sup.20 Q.sup.21 G.sup.22-R.sup.2 wherein R.sup.1 is CH.sub.3, C(O)CH.sub.3,C(O)CH.sub.3, C(O)CH.sub.2CH.sub.3, C(O)CH.sub.2CH.sub.2CH.sub.3, C(O)CH(CH.sub.3)CH.sub.3, C(O)CH.sub.2CH.sub.2CH.sub.2CH.sub.3, C(O)CH(CH.sub.3)CH.sub.2CH.sub.3, C(O)C.sub.6H.sub.5, C(O)CH.sub.2CH.sub.2(CH.sub.2CH.sub.2O).sub.1-5Me, dichlorobenzoyl (DCB), difluorobenzoyl (DFB), pyridinyl carboxlate (PyC) or amido-2-PEG, an amino protecting group, a lipid fatty acid group or a carbohydrate; and R.sup.2 is OH, NH.sub.2, NH(CH.sub.3), NHCH.sub.2CH.sub.3, NHCH.sub.2CH.sub.2CH.sub.3, NHCH(CH.sub.3)CH.sub.3, NHCH.sub.2CH.sub.2CH.sub.2CH.sub.3, NHCH(CH.sub.3)CH.sub.2CH.sub.3, NHC.sub.6H.sub.5, NHCH.sub.2CH.sub.2OCH.sub.3, NHOCH.sub.3, NHOCH.sub.2CH.sub.3, a carboxy protecting group, a lipid fatty acid group or a carbohydrate, wherein the angiogenic disorder is selected from the group consisting of angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, diabetic retinopathy, carcinomas of the breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract, female genital tract, male genital tract, endocrine glands, and skin; hemangiomas; melanomas; sarcomas; tumors of the brain, nerves, eyes, and meninges; leukemia; and lymphoma. 2. The method as claimed in claim 1, wherein R.sup.1 is C(O)CH.sub.3. 3. The method as claimed in claim 1, wherein R.sup.2 is NH.sub.2. 4. The method as claimed in claim 1, wherein the AA targeting compound is covalently connected to a linear or branched Linker of the formula --X-(recognition group Y)--Z--, or --X-(recognition group Y)--Z', wherein: X is attached to the AA targetingcompound via the side chain of K.sup.11, and is a biologically compatible connecting chain including any atom selected from the group consisting of C, H, N, 0, P, S, F, CL, Br, and I, and may comprise a polymer or block co-polymer, (recognition group Y) is an optionally present recognition group comprising at least a ring structure; and Z is a reactive group that is capable of forming a covalent bond with an amino acid side chain in a combining site of an antibody and Z' is an attachment moiety comprising a covalent link to an amino acid side in a combining site of an antibody. 5. The method as claimed in claim 4, wherein the (recognition group Y) has the optionally substituted structure: ##STR00284## wherein a, b, c, d, and e are independently carbon or nitrogen; f is carbon, nitrogen, oxygen, or sulfur; (recognition group Y) is attached to X and Z independently at any two ring positions of sufficient valence; and no more than four of a, b, c, d, e, or f are simultaneously nitrogen. 6. The method as claimed in claim 5, wherein a, b, c, d, and e are each carbon. 7. The method as claimed in claim 6, wherein (recognition group Y) is phenyl. 8. The method as claimed in claim 4, wherein Z if present is selected from the group consisting of substituted 1,3-diketones or acyl beta-lactams. 9. The method as claimed in claim 4, wherein Z if present has the structure: ##STR00285## and wherein Z' if present has the structure: ##STR00286## wherein q.dbd.0-5and Antibody-N-- if present is a covalent bond to a side chain in a combining site of an antibody. 10. The method as claimed in claim 9, wherein q.dbd.2. 11. The method as claimed in claim 4, wherein X is attached to side chain of K.sup.11, is substituted or unsubstituted and is selected from --R.sup.22--[CH.sub.2--CH.sub.2--O].sub.t--R.sup.23--, --R.sup.22-cycloalkyl-R.sup.23--, --R.sup.22-aryl-R.sup.23--, or --R.sup.22-heterocyclyl-R.sup.23--, wherein: R.sup.22 and R.sup.23 are independently a covalent bond, --O--, --S--, --NR.sup.b--, substituted or unsubstituted straight or branched chain C.sub.1-50 alkylene, substituted or unsubstituted straight or branched chain C.sub.1-50 heteroalkylene, substituted or unsubstituted straight or branched chain C.sub.2-50 alkenylene, or substituted or unsubstituted C.sub.2-50 heteroalkenylene; R.sup.b, at each occurrence, is independently hydrogen, substituted or unsubstituted C.sub.1-10 alkyl, substituted or unsubstituted C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl, or substituted or unsubstituted aryl-C.sub.0-6 alkyl; t.dbd.2-50; and the size of R.sup.22 and R.sup.23 are such that the backbone length of X remains 200 atoms or less. 12. The method as claimed in claim 4, wherein X is: ##STR00287## wherein v and w are each independently 1, 2, 3, 4, or 5 and are selected such that the backbone length of X is 6-12 atoms, and R.sup.b is hydrogen, substituted or unsubstituted C.sub.1-10 alkyl, substituted or unsubstituted C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl, or substituted or unsubstituted aryl-C.sub.0-6 alkyl. 13. The method as claimed in claim 12, wherein X--Y is: ##STR00288## wherein v.dbd.1 or 2; w.dbd.1 or 2 and R.sup.b is hydrogen. 14. The method as claimed in claim 4, wherein the compound comprises the structure: ##STR00289## wherein the AA targeting compound comprises SEQ ID N0:43. 15. The method as claimed claim 4, wherein the compound comprises the structure: ##STR00290## wherein the AA targeting compound comprises SEQ ID N0:43. 16. The method as claimed in claim 15, wherein the antibody is a catalytic antibody. 17. The method as claimed in claim 16, wherein the antibody is an aldolase catalytic antibody. 18. The method as claimed in claim 17, wherein the antibody is a full length antibody, Fab, Fab', F(ab').sub.2, F.sub.v, dsF.sub.v, scF.sub.v, V.sub.H, diabody, or minibody comprising V.sub.H and V.sub.L domains from h38c2, or is an antibody comprising the V.sub.H and V.sub.L domains from h38c2 and a constant domain selected from the group consisting of IgG1, IgG2, IgG3, and IgG4, or is h38c2 IgG1. 19. The method as claimed in claim 15, wherein the Antibody comprises SEQ ID NO:189 and SEQ ID NO:190. 20. The method as claimed in claim 1, wherein the compound comprises the structure: ##STR00291## wherein the AA targeting compound comprises SEQ ID N0:43, and the antibody comprises SEQ ID NO:189 and SEQ ID NO:190. 21. The method as claimed in claim 20, further comprising a therapeutically effective amount of one or more chemotherapeutic agents. 22. A method as claimed in claim 21, wherein the chemotherapeutic agent is selected from the group consisting of Aldesleukin, Alemtuzumab, Alitretinoin, Allopurinol, Altretamine, Anastrozole, Arsenic trioxide, Asparaginase, Bevacizumab, Bexarotene capsules, Bexarotene gel, Bleomycin, Busulfan intravenous, Busulfan oral, Calusterone , Capecitabine, Carboplatin, Carmustine, Celecoxib, Cetuximab, Chlorambucil, Cinacalchet, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, actinomycin D, Danileukin diftitox, Darbepoetin alfa, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, Dromostanolone Propionate, Elliott's B Solution, Epoetin alfa/beta, Erlotinib, Estramustine, Etoposide phosphate, Etoposide, Exemestane, Filgrastim, Floxuridine, Fludarabine, Fluorouracil, Fulvestrant, Gemcitabine, Gemtuzumab ozogamicin, Goserelin acetate, Hydroxyurea, Ibritumomab tiuxetan, Idarubicin, Ifosfamide, Imatinib mesylate, Interferon alfa-2a, Irinotecan, Letrozole, Leucovorin, Levamisole, Lomustine, Meclorethamine, nitrogen mustard, Megestrol acetate, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methoxsalen, Mitomycin, Mitotane, Mitoxantrone, Nandrolone phenpropionate, Nelarabine, Nofetumomab, Oprelvekin, Oxaliplatin, Paclitaxel, Palonosetron, Pamidronate, Pegademase, Pegaspargase, Pegfilgrastim, Pemetrexed, Pentostatin, Pipobroman, Plicamycin, mithramycin, Porfimer sodium, Procarbazine, Rasburicase, Rituximab, Sargramostim, Streptozocin, Talc, Tamoxifen, Temozolomide, Teniposide, Testolactone, Thioguanine, Thiotepa, Topotecan, Toremifene, Tositumomab, Trastuzumab, Tretinoin, Uracil Mustard, Valrubicin, Vinblastine, Vincristine, Vinorelbine, Zoledronate, Sorafenib, Sutent, Thalomid, Revlimid, Vatalanib, ZD-6474, Neovastat, GSK-786024, AEE-788, AG-13736, AMG706, AZD-2171, BIBF-1120, CP-547,632, Midostaurin, SU-6668, CDP-791, PI-88, PCK-3145, Atiprimod, A6, Angiostatin, Cilengitide, Enodstatin, rPF4, Vitakin, Volociximab, 2-methoxyestradiol, AP-23573, Cancertinib, Actimid, Combretastatin A4 prodrug, Endo Tag 1, Enzastaurin, Ceflatonin, Silipide, INGN-241, OSI-461, Patupilone, Squalamine, Tacedinaline, UCN-01, UK-356202, Prednisolone, Methyl-prednisolone, Dexamethasone, and Epirubicin. 23. A method as claimed in claim 1, further comprising a therapeutically effective amount of one or more chemotherapeutic agents. 24. A method as claimed in claim 22, wherein the chemotherapeutic agent is selected from the group consisting of Aldesleukin, Alemtuzumab, Alitretinoin, Allopurinol, Altretamine, Anastrozole, Arsenic trioxide, Asparaginase, Bevacizumab, Bexarotene capsules, Bexarotene gel, Bleomycin, Busulfan intravenous, Busulfan oral, Calusterone , Capecitabine, Carboplatin, Carmustine, Celecoxib, Cetuximab, Chlorambucil, Cinacalchet, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, actinomycin D, Danileukin diftitox, Darbepoetin alfa, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, Dromostanolone Propionate, Elliott's B Solution, Epoetin alfa/beta, Erlotinib, Estramustine, Etoposide phosphate, Etoposide, Exemestane, Filgrastim, Floxuridine, Fludarabine, Fluorouracil, Fulvestrant, Gemcitabine, Gemtuzumab ozogamicin, Goserelin acetate, Hydroxyurea, Ibritumomab tiuxetan, Idarubicin, Ifosfamide, Imatinib mesylate, Interferon alfa-2a, Irinotecan, Letrozole, Leucovorin, Levamisole, Lomustine, Meclorethamine, nitrogen mustard, Megestrol acetate, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methoxsalen, Mitomycin, Mitotane, Mitoxantrone, Nandrolone phenpropionate, Nelarabine, Nofetumomab, Oprelvekin, Oxaliplatin, Paclitaxel, Palonosetron, Pamidronate, Pegademase, Pegaspargase, Pegfilgrastim, Pemetrexed, Pentostatin, Pipobroman, Plicamycin, mithramycin, Porfimer sodium, Procarbazine, Rasburicase, Rituximab, Sargramostim, Streptozocin, Talc, Tamoxifen, Temozolomide, Teniposide, Testolactone, Thioguanine, Thiotepa, Topotecan, Toremifene, Tositumomab, Trastuzumab, Tretinoin, Uracil Mustard, Valrubicin, Vinblastine, Vincristine, Vinorelbine, Zoledronate, Sorafenib, Sutent, Thalomid, Revlimid, Vatalanib, ZD-6474, Neovastat, GSK-786024, AEE-788, AG-13736, AMG706, AZD-2171, BIBF-1120, CP-547,632, Midostaurin, SU-6668, CDP-791, PI-88, PCK-3145, Atiprimod, A6, Angiostatin, Cilengitide, Enodstatin, rPF4, Vitakin, Volociximab, 2-methoxyestradiol, AP-23573, Cancertinib, Actimid, Combretastatin A4 prodrug, Endo Tag 1, Enzastaurin, Ceflatonin, Silipide, INGN-241, OSI-461, Patupilone, Squalamine, Tacedinaline, UCN-01, UK-356202, Prednisolone, Methyl-prednisolone, Dexamethasone, and Epirubicin.

Details for Patent 8,912,148

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2026-11-10
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	06/01/1989		2026-11-10
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234			2026-11-10
Amgen, Inc.	PROCRIT	epoetin alfa	Injection	103234			2026-11-10